ScienceDex / Researcher record
Michael G Agadjanyan
- Institute for Molecular Medicine (no department on record)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
- Program Leader
- R01 Holder
- Top 10% Funded
- Early Career
NIH Funding · FY2026
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $4,035,475 | 2 | #1,604 |
| 2025 | $9,446,281 | 3 | #475 |
| 2026 | $8,798,226 | 3 | #1,090 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20242 records
- FY20253 records
- FY2026 · selected3 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 1870529Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2026 award records by amount
NIH award records listing Michael G Agadjanyan as a PI. Multi-PI records show the full award amount for context.
- 5R01AG092949-02R01Contact PIFDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.$4.9Maward amount
- 5R01AG074983-05R01Contact PISafety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2.1Maward amount
- 5U01AG084528-03U01Contact PIIND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)$1.8Maward amount
Award organization
Organizations that administered FY2026 awards listing Michael G Agadjanyan as a PI.
FY2026 award administered by Institute for Molecular Medicine (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardInstitute for Molecular Medicine
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #1604
- 2024Entered Top 25% NationallyRanked #1604
- 2024Entered Top 10% NationallyRanked #1604
- 2025$5M Cumulative Funding
- 2025$10M Cumulative Funding
- 2025Entered Top 5% NationallyRanked #475
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Michael G Agadjanyan.